InflaRx Newsroom

H.C. Wainwright Maintains InflaRx(IFRX.US) With Buy Rating, Maintains Target Price $8

Futu NewsDec 21 03:31

InflaRx Analyst Ratings

BenzingaDec 21 00:01

LifeSci Capital Maintains InflaRx(IFRX.US) With Hold Rating

Futu NewsNov 16 03:31

H.C. Wainwright Maintains InflaRx(IFRX.US) With Buy Rating, Maintains Target Price $8

Futu NewsNov 15 23:31

LifeSci Capital Maintains InflaRx(IFRX.US) With Hold Rating

Futu NewsNov 11 20:34

LifeSci Capital Keeps Their Hold Rating on InflaRx (IFRX)

TipRanksNov 11 20:09

H.C. Wainwright Maintains InflaRx(IFRX.US) With Buy Rating, Maintains Target Price $8

Futu NewsNov 11 19:31

InflaRx's Promising Market Potential and Financial Stability Justify Buy Rating

TipRanksNov 11 19:27

H.C. Wainwright Maintains InflaRx(IFRX.US) With Buy Rating, Maintains Target Price $8

Futu NewsSep 25 22:31

InflaRx Buy Rating Backed by Promising Drug Prospects and Financial Stability

TipRanksAug 13 21:59

Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Krystal Biotech (KRYS) and InflaRx (IFRX)

TipRanksAug 12 20:37

InflaRx Buy Rating Affirmed: Financial Stability and Gohibic's Market Potential

TipRanksAug 9 00:29

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

BenzingaJun 25 01:32

InflaRx Analyst Ratings

BenzingaJun 25 01:32

InflaRx Analyst Ratings

BenzingaJun 6 19:10

InflaRx's Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D Insights

TipRanksMay 10 13:35

InflaRx Analyst Ratings

BenzingaMay 9 18:55

HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target

BenzingaMay 9 18:55

InflaRx Buy Rating: Strong Financials and High Potential of Gohibic for PG Treatment

TipRanksMay 9 18:35

LifeSci Capital Remains a Hold on InflaRx (IFRX)

TipRanksMay 9 04:50